α2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 1, 1999, Pages 65-73

  Yoles, Eti ^a   Wheeler, Larry A ^b   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 191103; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; TIMOLOL; UNCLASSIFIED DRUG; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; NEUROPROTECTIVE AGENT; QUINOXALINE DERIVATIVE; YOHIMBINE;

ACTION POTENTIAL; ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GLAUCOMA; INTRAOCULAR PRESSURE ABNORMALITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; RAT; ANIMAL; CELL COUNT; DISEASE MODEL; DRUG EFFECT; METABOLISM; NERVE FIBER; OPTIC NERVE; OPTIC NERVE DISEASE; OPTIC NERVE INJURY; PATHOLOGY; RETINA GANGLION CELL; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AXONS; CELL COUNT; CELL SURVIVAL; CLONIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OPTIC NERVE; OPTIC NERVE DISEASES; OPTIC NERVE INJURIES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RETINAL GANGLION CELLS; TIMOLOL; YOHIMBINE;

EID: 0032622411     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma. 1996;5:427-432.
2. Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Levture. Am J Ophthalmol. 1996;121:473-483.
3. Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol. 1998;42:367-372.
4. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
5. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:497-503.
6. Bittiger H, Herd J, Wigger N. Are only alpha-2-adrenergic receptors present in bovine retina? Nature. 1980;87:645-647.
7. Wikberg Matsson A, Wikberg JE, Uhlen S. Characterization of alpha 2-adrenoceptor subtypes in the porcine eye: identification of alpha 2A-adrenoceptors in the choroid, ciliary body and iris, and alpha 2A- and alpha 2C-adrenoceptors in the retina. Exp Eye Res. 1996; 63:57-66.
8. Elena PP, Kosina Boix M, Denis P, Moulin G, Lapalus P. Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography. Ophthalmic Res. 1989:309-314.
9. 3H)noradrenaline to bovine membrane of the retina. Evidence for the existence of alpha 2-receptors. Vision Res. 1982;22:1401-1407.
10. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and closing studies. Surv Ophthalmol. 1996;1:519-526.
11. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M. Neuroprotection by the alpha-2 adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology. 1993;79:306-312.
12. Hoffman WE, Cheng MA, Thomas C, Baughman VL, Albrecht RF. Clonidine decreases plasma catecholamines and improves outcome from incomplete ischemia in the rat. Anesth Analg. 1991; 73:460-464.
13. Nacif-Coelho C, Correa-Sales C, Chang LL, Maze M. Perturbation of ion channel conductance alters the hypnotic response to the alpha-2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat. Anesthesiology 1994;81:1527-1534.
14. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996; 16:5986-5992.
15. Yoles E, Schwartz M. Degeneration of spared neurons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol. 1998;153:1-7.
16. Yoles E, Schwartz M. Elevation of intraocular glutamate in rats with partial lesion of the optic nerve. Arch Ophthalmol. 1998;116:906-910.
17. Yoles E, Muller S, Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma. 1997;14:665-675.
18. Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981;72:413-415.
19. Munk S, Gluchowski C, Dolby L, et al. Analogs of UK14,304 as alpha-2 adrenoreceptor agonists: twist and agent polarity as design elements. Bioorg Med Chem Lett. 1994;4:459-462.
20. Burke J, Manlapaz C, Kharlamb A, et al. In: Lainer SM, Limbirdeds LE. Therapeutic Use of Alpha-2 Adrenoreceptor Agonists in Glaucoma in Alpha-Adrenergic Receptors. Amsterdam, The Netherlands: Harwood Academic; 1997:179-187.
21. Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology. 1991;76:581-605.
22. Assia E, Rosner M, Helkin M, Schwartz M. Temporal parameters and low energy laser irradiation for optimal delay of posttraumatic degeneration of rat optic nerve. Brain Res. 1989;476:205-212.
23. Duvdevani R, Rosner M, Belkin M, Sautter J, Sabel BA, Schwartz M. Graded crash of the rat optic nerve as a brain injury model: combining electrophysiological and behavioral outcome. Restor Neurol Neurosci. 1990;2:31-38.
24. Sautter J, Schwartz M, Duvdevani R, Sabel BA. GMI ganglioside treatment reduces visual deficits after graded crush of the rat optic nerve. Brain Res. 1991;565:23-33.
25. Yoles E, Zalish M, Lavie V, Duvdevani R, Ben-Bassat S, Schwartz M. GMI reduces early injury-induced metabolic deficits and subsequent degeneration in the rat optic nerve. Invest Ophthalmol Vis Sci. 1992;33:3586-3591
26. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma. 1996;13:49-57.
27. 3H]Rauwolscine binding sites in the brain of male tree shrews are related to social status. Brain Res. 1992;597:131-137.
28. Pearson HE, Thompson TP. Atrophy and degeneration of ganglion cells in central retina following loss of postsynaptic target neurons in the dorsal lateral geniculate nucleus of the adult cat. Exp Neurol. 1993;119:113-119.
29. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994;5:156-170.
30. Zauner A, Bullock R. The role of excitatory amino acids in severe brain trauma: opportunities for therapy. A review. J Neurotrauma. 1995;12:547-554.
31. Dawson DA. Nitric oxide and focal cerebral ischemia: multiplicity of actions and diverse outcome. Cerebrovasc Brain Metab Rev. 1994;6:299-324.
32. Novack TA, Dillon MC, Jackson WT. Neurochemical mechanisms in brain injury and treatment: a review. J Clin Exp Neuropsychol. 1996;18:685-706.
33. Katayama Y, Maeda T, Koshinaga M, Kawamata T, Tsubokawa T. Role of excitatory amino acid-mediated ionic fluxes in traumatic brain injury. Brain Pathol. 1995;5:427-435.
34. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618-1624.
35. Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol Chem Neuropathol. 1994;23:125-135.
36. Peng M, Li Y, Luo Z, Liu C, Laties AM, Wen R. A novel mechanism regulating expression of GFAP mediated by PI3K-MAPK signaling pathway in Muller cells in response to α2-adrenergic agonists (abstract 652.7). Soc Neurosci. 1997;23;1671.
37. Hasson DW, Lai RK, Chun T, Wheeler LA. Functional protection of rat retina from ischemic injury by brimonidine. Soc Neurosci. 1997;23:168.
38. Lai RK, Hasson DW, Wheeler LA. Neuroprotective effect of brimonidine [ARVO Abstracts]. Invest Ophthalmol Vis Sci. 1997; 38(4):S590. Abstract nr 2750.
39. Lai RK, Hasson DW, Chun T, Wheeler LA. Neuroprotective effect of ocular hypotensive agent brimonidine. XIth Congress of the European Society of Ophthalmology. Bologna, Italy: Monduzzi Editore; 1997:439-444.